XML 50 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Redeemable Convertible Preferred Stock and Equity (Deficit) - USD ($)
$ in Thousands
Total
Astra Zeneca [Member]
FibroGen Europe [Member]
Senior Preferred Stock [Member]
Senior Preferred Stock [Member]
Astra Zeneca [Member]
Senior Preferred Stock [Member]
FibroGen Europe [Member]
Junior Preferred Stock [Member]
Junior Preferred Stock [Member]
Astra Zeneca [Member]
Junior Preferred Stock [Member]
FibroGen Europe [Member]
Common Stock [Member]
Common Stock [Member]
Astra Zeneca [Member]
Common Stock [Member]
FibroGen Europe [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Astra Zeneca [Member]
Additional Paid-in Capital [Member]
FibroGen Europe [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Loss [Member]
Astra Zeneca [Member]
Accumulated Other Comprehensive Loss [Member]
FibroGen Europe [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Astra Zeneca [Member]
Accumulated Deficit [Member]
FibroGen Europe [Member]
Noncontrolling Interest [Member]
Noncontrolling Interest [Member]
Astra Zeneca [Member]
Noncontrolling Interest [Member]
FibroGen Europe [Member]
Balance at Dec. 31, 2012 $ (46,252)     $ 168,436     $ 136,313     $ 132     $ 37,606     $ (167)     $ (247,836)     $ 27,700    
Balance, Shares at Dec. 31, 2012       38,340,182     46,460,057     13,167,138                            
Net loss (14,943)     $ 0     $ 0     $ 0     0     0     (14,943)     0    
Change in unrealized loss on investments (2,676)     0     0     0     0     (2,676)     0     0    
Foreign currency translation adjustments (665)     0     0     0     0     (665)     0     0    
Issuance of Series A Preferred to non-controlling interests 175     0     0     0     0     0     0     175    
Stock options exercised 84     $ 0     $ 0     $ 0     84     0     0     0    
Stock options exercised , Shares       0     0     34,126                            
Stock-based compensation 3,444     $ 0     $ 0     $ 0     3,444     0     0     0    
Balance at Dec. 31, 2013 (60,833)     $ 168,436     $ 136,313     $ 132     41,134     (3,508)     (262,779)     27,875    
Balance, Shares at Dec. 31, 2013       38,340,182     46,460,057     13,201,264                            
Net loss (59,504)     $ 0     $ 0     $ 0     0     0     (59,504)     0    
Change in unrealized loss on investments (1,723)     0     0     0     0     (1,723)     0     0    
Foreign currency translation adjustments 2,082     0     0     0     0     2,082     0     0    
Stock options exercised 1,694     $ 0     $ 0     $ 5     1,689     0     0     0    
Stock options exercised , Shares       0     0     539,971                            
Stock-based compensation 18,698     $ 0     $ 0     $ 0     18,698     0     0     0    
Balance at Dec. 31, 2014 240,676     $ 0     $ 0     $ 590     546,247     (3,149)     (322,283)     19,271    
Balance, Shares at Dec. 31, 2014       0     0     59,046,296                            
Conversion of preferred stock to common stock $ 168,436   $ 0     $ 0     $ 0 $ 339   $ 10 $ 304,410   $ 8,594 $ 0   $ 0 $ 0   $ 0 $ 0    
Conversion of preferred stock to common stock       $ (168,436)     $ (136,313)                                 $ (8,604)
Conversion of preferred stock to common stock, shares           0     0 33,919,954   958,996                        
Conversion of preferred stock to common stock, shares 0     (38,340,182)     (46,460,057)     0     0     0     0     0    
Initial Public Offering, net of underwriting discounts, commission and issuance costs $ 151,826     $ 0     $ 0     $ 93     $ 151,733     $ 0     $ 0     $ 0    
Initial Public Offering, net of underwriting discounts, commission and issuance costs, shares       0     0     9,315,000                            
Astra Zeneca private placement   $ 20,000     $ 0     $ 0     $ 11     $ 19,989     $ 0     $ 0     $ 0  
Astra Zeneca private placement, Shares         0     0     1,111,111                          
Net loss (85,779)     $ 0     $ 0     $ 0     0     0     (85,779)     0    
Change in unrealized loss on investments (164)     0     0     0     0     (164)     0     0    
Foreign currency translation adjustments 1,662     0     0     0     0     1,662     0     0    
Stock options exercised 10,112     $ 0     $ 0     $ 24     10,088     0     0     0    
Stock options exercised , Shares       0     0     2,361,633                            
Stock-based compensation 27,681     $ 0     $ 0     $ 0     27,681     0     0     0    
Balance at Dec. 31, 2015 196,825     $ 0     $ 0     $ 620     586,647     (1,651)     (408,062)     19,271    
Balance, Shares at Dec. 31, 2015       0     0     61,985,079                            
Shares issued upon vesting of restricted stock units and purchases made under the employee stock purchase plan, shares       0     0     456,355                            
Shares issued upon vesting of restricted stock units and purchases made under the employee stock purchase plan 2,595     $ 0     $ 0     $ 5     2,590     0     0     0    
True up of issuance costs related to initial public offering and common stock sold by FibroGen Europe 42     0     0     0     42     0     0     0    
Warrants exercised $ 0     $ 0     $ 0     $ 1     $ (1)     $ 0     $ 0     $ 0    
Warrants exercised, Shares                   120,795